Pfizer (PFE.US) — market event timeline

NashNova tracks 2 market events mentioning Pfizer (PFE.US) between 2026-06-22 and 2026-06-24, each with a dated one-line analysis of how the event relates to the asset.

  1. Pfizer's Ibrance Receives FDA Approval for New Breast Cancer Indication

    Ibrance is Pfizer's core oncology product, and the new indication expansion into HER2-positive breast cancer directly enlarges its potential market size.

  2. Pfizer's Lung Cancer Drug Sigvotatug Vedotin Misses Primary Endpoint in Phase 3 Trial

    Central to the event, sigvotatug vedotin's Phase 3 trial missed its primary endpoint, directly impacting valuation expectations for Pfizer's oncology pipeline.

For research and information only — not investment advice.

Pfizer (PFE.US) — News & AI Analysis · NashNova